Orchestra Biomed Holdings, INC

Orchestra BioMed Holdings, Inc. announced new executive compensation plans, including a cash bonus program tied to clinical trial milestones and financial objectives, alongside revised RSU vesting and salary increases for its CEO and COO.

Orchestra BioMed expects to receive up to $21 million in proceeds from the acquisition of its strategic holding, Vivasure Medical, by Haemonetics Corporation.

Orchestra BioMed Holdings, Inc. announced significant strategic financing totaling nearly $150 million and provided updates on its pivotal AVIM Therapy and Virtue SAB clinical trials.

Orchestra BioMed Holdings, Inc. highlights its pivotal-stage therapies, strategic partnerships, and over $147 million in new capital commitments to fund operations into Q4 2027.

Orchestra BioMed has entered new strategic agreements with Terumo, securing $30 million in funding and initiating its pivotal U.S. Virtue SAB clinical trial for coronary in-stent restenosis.

Orchestra BioMed Holdings, Inc. successfully completed a public offering and private placement, raising approximately $56.2 million to advance its AVIM therapy and Virtue SAB programs.

Orchestra BioMed reports increased net losses in Q3 2025, but secures significant new financing and initiates a pivotal clinical trial for Virtue SAB, while terminating its Terumo agreement.

Orchestra BioMed Holdings, Inc. reported increased Q2 losses and R&D expenses but secured $76.2 million in new capital and extended debt amortization, providing funding into late 2027.

Orchestra BioMed Holdings reports increased revenue but a larger net loss in Q1 2025, while also expressing substantial doubt about its ability to continue as a going concern due to insufficient capital.

Orchestra BioMed Holdings announced its Q3 2024 financial results, highlighting a revenue increase and a new $50 million loan facility, while also noting ongoing research and development expenses.

Orchestra BioMed Holdings reported a net loss of $29.4 million for the first six months of 2024, with ongoing investments in research and development.

Orchestra BioMed Holdings reported a net loss of $13.5 million for the first quarter of 2024, while highlighting advancements in its BackBeat CNT and Virtue SAB programs.

Orchestra BioMed Holdings, Inc. reported a net loss of $52.7 million for 2025, while advancing key clinical trials for its AVIM Therapy and Virtue SAB product candidates and securing new financing.

Orchestra BioMed Holdings details its 2024 financial performance, highlighting progress in clinical trials and strategic partnerships amid ongoing financial challenges.

Orchestra BioMed's 10-K filing details its authorized and outstanding stock, warrants, registration rights, and corporate governance, providing a comprehensive overview of its securities structure.

Orchestra BioMed Holdings, Inc. reports a Form 4 filing detailing stock transactions by Director Eric S. Fain, including RSU awards and share withholding for tax obligations.

David Pacitti, a Director at Orchestra BioMed Holdings, Inc., acquired restricted stock units and stock options on June 23, 2026, as part of his compensation.

Orchestra BioMed Holdings, Inc. director Chris Cleary acquired stock options and had shares withheld for tax obligations related to RSU vesting.

Orchestra BioMed Holdings, Inc. reports that Director Pamela Ann Connealy was granted restricted stock units and stock options on June 23, 2026.

Orchestra BioMed Holdings, Inc. director Aryeh Jason was granted stock options for 42,553 shares.

Orchestra BioMed Holdings, Inc. Director John Prosper Mack reported transactions involving restricted stock units and common stock.

Orchestra BioMed Holdings, Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on June 24, 2025, with voting matters including the election of directors and ratification of the company's independent auditor.

Orchestra BioMed Holdings will hold its 2025 Annual Meeting of Stockholders virtually on June 24, 2025, to elect directors and ratify the appointment of its independent accounting firm.

Orchestra BioMed Holdings, Inc. will hold its annual meeting on June 20, 2024, and is soliciting votes on the election of directors and ratification of its accounting firm.

Orchestra BioMed Holdings will hold its 2024 Annual Meeting of Stockholders virtually on June 20, 2024, to elect directors and ratify the appointment of Ernst & Young LLP as its independent accounting firm.

RTW Investments, LP and affiliated funds have increased their beneficial ownership in Orchestra Biomed Holdings, Inc. to 19.2% following the cashless exercise of pre-funded warrants.

RTW Investments and its affiliated funds have increased their beneficial ownership in Orchestra BioMed Holdings, Inc. to 19.7% by raising the maximum percentage under pre-funded warrants.

RTW Investments and its affiliated funds increased their beneficial ownership in Orchestra BioMed Holdings, Inc. to 15.4% through the purchase of pre-funded warrants in a public offering.

RTW Investments, LP and its affiliated funds have increased their beneficial ownership in Orchestra Biomed Holdings, Inc. to 21.7% through recent open market purchases.

Medtronic plc and Covidien Group S.a.r.l. have jointly reported a beneficial ownership of 17.8% in Orchestra BioMed Holdings, Inc. common stock.

Tasso Partners, LLC and Dana Lorenzo have jointly filed a Schedule 13G, disclosing beneficial ownership of 5.5% of Orchestra BioMed Holdings, Inc.'s common stock.

Perceptive Advisors, Joseph Edelman, and Perceptive Life Sciences Master Fund collectively reported a 9.99% beneficial ownership stake in Orchestra BioMed Holdings, Inc.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 3.7% passive beneficial ownership stake in Orchestra BioMed Holdings, Inc. as of March 31, 2025.

Medtronic plc and its subsidiary Covidien Group S.a.r.l. have disclosed a combined beneficial ownership of 15.4% in Orchestra BioMed Holdings, Inc., holding 5,868,916 shares of common stock as of December 31, 2024.